Stephen Ian Walimbwa - Infectious Diseases

Author Information

Stephen Ian Walimbwa is affiliated with the Infectious Diseases Institute at Makerere University College of Health Sciences in Kampala, Uganda. His work primarily focuses on infectious diseases, with a particular emphasis on HIV treatment and pharmacokinetics. His affiliation with a leading health sciences institution underscores his active involvement in significant clinical and pharmacological research initiatives.

Research Contributions

Stephen Ian Walimbwa has made significant contributions to the field of infectious diseases, especially in the area of HIV treatment. His research includes studies on the efficacy and safety of various HIV treatment regimens, the pharmacokinetics of co-administered drugs, and genetic factors affecting clinical outcomes in HIV-infected patients. Notable studies include analyses of drug-drug interactions involving antiretroviral therapies and evaluations of pharmacokinetics in specific populations, such as those involving remdesivir and dolutegravir. His work provides valuable insights into optimizing treatment strategies for HIV and other infectious diseases.

Aliases

Stephen Ian Walimbwa is known by several aliases, including Stephen Walimbwa, Stephen I Walimbwa, Stephen I. Walimbwa, and S. Walimbwa. These variations are commonly used in academic publications and databases.

Publication and Citation Metrics

Metric	Value
Total Citations	299
h-index	8
Total Publications	21

Publications:

Efficacy and safety of dolutegravir or darunavir in combination with lamivudine plus either zidovudine or tenofovir for second-line treatment of HIV infection (NADIA): week 96 results from a prospective, multicentre, open-label, factorial, randomised, non-inferiority trial.

DOI: 10.1016/s2352-3018(22)00092-3

Year: 2022

Dolutegravir pharmacokinetics during co-administration with either artemether/lumefantrine or artesunate/amodiaquine.

DOI: 10.1093/jac/dkab022

Year: 2021

Dolutegravir or Darunavir in Combination with Zidovudine or Tenofovir to Treat HIV.

DOI: 10.1056/NEJMoa2101609

Year: 2021

Genetic factors associated with tuberculosis-related clinical outcomes in HIV-infected Black-African patients: a systematic review and meta-analysis.

DOI: 10.2217/pgs-2021-0096

Year: 2021

An open-label, randomized, single intravenous dosing study to investigate the effect of fixed-dose combinations of tenofovir/lamivudine or atazanavir/ritonavir on the pharmacokinetics of remdesivir in Ugandan healthy volunteers (RemTLAR)

DOI: 10.1186/s13063-021-05752-1

Year: 2021

An open-label, randomized, single intravenous dosing study to investigate the effect of fixed dose combinations of tenofovir/lamivudine or atazanavir/ritonavir on the pharmacokinetics of remdesivir in Ugandan healthy volunteers (RemTLAR)

DOI: 10.21203/RS.3.RS-377098/V1

Year: 2021

Development and validation of a UHPLC-MS/MS method for quantification of the prodrug remdesivir and its metabolite GS-441524: a tool for clinical pharmacokinetics of SARS-CoV-2/COVID-19 and Ebola virus disease

DOI: 10.1093/jac/dkaa152

Year: 2020

An Individual Participant Data Population Pharmacokinetic Meta-analysis of Drug-Drug Interactions between Lumefantrine and Commonly Used Antiretroviral Treatment

DOI: 10.1128/AAC.02394-19

Year: 2020

Infant Exposure to Dolutegravir Through Placental and Breast Milk Transfer: A Population Pharmacokinetic Analysis of DolPHIN-1

DOI: 10.1093/cid/ciaa1861

Year: 2020

Drug-drug Interactions between Lumefantrine and Commonly-used Antiretroviral Treatment: An Individual Participant Data Population Pharmacokinetic Meta-Analysis.

DOI: 10.1128/aac.02394-19

Year: 2020

What Treatments are Available?

What is the Role of Genomics in Tracking Disease Outbreaks?

What are Immunodeficiency Disorders?

How is Inherited Immunity Studied?

What is Safety in the Context of Infectious Diseases?

What is Toxicity?

How is Dengue Diagnosed?

What is the Prognosis for Patients with ARDS?

What are the benefits of using Dexamethasone in COVID-19?

What is Acute Respiratory Distress Syndrome (ARDS)?

Partnered Content Networks

Relevant Topics